Press Releases

Worldwide Ocaliva net sales of $46.6 million in the third quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019 Conference call scheduled for 8:30 a.m.

NEW YORK , Oct. 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its third quarter 2018 financial results prior

NEW YORK , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the

NEW YORK , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the

Worldwide Ocaliva net sales of $43.2 million in the second quarter of 2018 Leading Phase 3 NASH program continues to advance: REGENERATE trial in NASH patients with advanced liver fibrosis expected to report data in the first half of 2019 Conference call scheduled for 8:30 a.m.

NEW YORK , July 26, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2018 financial results prior

NEW YORK , June 07, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the

Worldwide Ocaliva net sales of $35.2 million in the first quarter of 2018 2018 worldwide Ocaliva net sales currently expected to be between $170 million and $185 million Continuing to advance leading NASH Phase 3 program: REGENERATE trial in non-cirrhotic NASH patients with liver fibrosis on track

NEW YORK , May 01, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its first quarter 2018 financial results prior

NEW YORK , April 24, 2018 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals , Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that its Board of Directors has appointed